René Bruno

5.9k total citations
128 papers, 4.7k citations indexed

About

René Bruno is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Statistics and Probability. According to data from OpenAlex, René Bruno has authored 128 papers receiving a total of 4.7k indexed citations (citations by other indexed papers that have themselves been cited), including 78 papers in Oncology, 31 papers in Pulmonary and Respiratory Medicine and 26 papers in Statistics and Probability. Recurrent topics in René Bruno's work include Colorectal Cancer Treatments and Studies (30 papers), Cancer Treatment and Pharmacology (29 papers) and Cancer Immunotherapy and Biomarkers (25 papers). René Bruno is often cited by papers focused on Colorectal Cancer Treatments and Studies (30 papers), Cancer Treatment and Pharmacology (29 papers) and Cancer Immunotherapy and Biomarkers (25 papers). René Bruno collaborates with scholars based in France, United States and Switzerland. René Bruno's co-authors include Laurent Claret, Jianfeng Lü, Guy Montay, Nicole Vivier, Steve Eppler, J. Vergniol, Lewis B. Sheiner, Athanassios Iliadis, François Mercier and Bert L. Lum and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Clinical Cancer Research.

In The Last Decade

René Bruno

127 papers receiving 4.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
René Bruno France	35	2.8k	1.0k	913	700	668	128	4.7k
Mourad Tighiouart United States	38	1.7k 0.6×	930 0.9×	1.6k 1.8×	700 1.0×	311 0.5×	152	5.0k
Shivaani Kummar United States	47	3.5k 1.3×	1.5k 1.5×	3.3k 3.6×	1.3k 1.8×	371 0.6×	296	7.0k
Julia A. Beaver United States	39	2.7k 1.0×	1.5k 1.5×	1.1k 1.2×	1.1k 1.5×	432 0.6×	131	4.8k
Shenghui Tang United States	39	2.9k 1.1×	1.8k 1.8×	1.2k 1.3×	855 1.2×	713 1.1×	116	5.3k
Robert Justice United States	40	2.5k 0.9×	1.7k 1.6×	2.8k 3.1×	871 1.2×	465 0.7×	61	6.4k
Andrew Kramar France	41	1.9k 0.7×	1.1k 1.0×	1.1k 1.2×	809 1.2×	711 1.1×	102	4.6k
Louise B. Grochow United States	32	4.0k 1.5×	1.5k 1.4×	1.3k 1.4×	646 0.9×	169 0.3×	59	6.6k
Markus Joerger Switzerland	37	2.2k 0.8×	1.1k 1.1×	1.5k 1.6×	776 1.1×	179 0.3×	215	4.6k
Peter H. O’Donnell United States	34	3.7k 1.3×	1.0k 1.0×	1.0k 1.1×	436 0.6×	209 0.3×	171	6.3k
Lisa Wang Canada	42	1.8k 0.7×	1.2k 1.2×	1.7k 1.9×	647 0.9×	257 0.4×	191	5.1k

Countries citing papers authored by René Bruno

Since Specialization

Citations

This map shows the geographic impact of René Bruno's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by René Bruno with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites René Bruno more than expected).

Fields of papers citing papers by René Bruno

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by René Bruno. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by René Bruno. The network helps show where René Bruno may publish in the future.

Co-authorship network of co-authors of René Bruno

This figure shows the co-authorship network connecting the top 25 collaborators of René Bruno. A scholar is included among the top collaborators of René Bruno based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with René Bruno. René Bruno is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Marchand, Mathilde, António Gonçalves, François Mercier, et al.. (2024). Tumor growth and overall survival modeling to support decision making in phase Ib/II trials: A comparison of the joint and two‐stage approaches. CPT Pharmacometrics & Systems Pharmacology. 13(6). 1017–1028. 3 indexed citations

Benzekry, Sébastien, Abdessamad El Kaoutari, Bruno Gomes, et al.. (2024). Predicting Survival in Patients with Advanced NSCLC Treated with Atezolizumab Using Pre‐ and on‐Treatment Prognostic Biomarkers. Clinical Pharmacology & Therapeutics. 116(4). 1110–1120. 6 indexed citations

Bruno, René, Pascal Chanu, Matts Kågedal, et al.. (2023). Support to early clinical decisions in drug development and personalised medicine with checkpoint inhibitors using dynamic biomarker-overall survival models. British Journal of Cancer. 129(9). 1383–1388. 13 indexed citations

Shemesh, Colby S., Phyllis Chan, Mathilde Marchand, et al.. (2023). Early Decision Making in a Randomized Phase II Trial of Atezolizumab in Biliary Tract Cancer Using a Tumor Growth Inhibition‐Survival Modeling Framework. Clinical Pharmacology & Therapeutics. 114(3). 644–651. 4 indexed citations

Krishnan, Sreenath M., Lena E. Friberg, François Mercier, et al.. (2023). Multistate Pharmacometric Model to Define the Impact of Second‐Line Immunotherapies on the Survival Outcome of the IMpower131 Study. Clinical Pharmacology & Therapeutics. 113(4). 851–858. 8 indexed citations

Gonçalves, António, Mathilde Marchand, Phyllis Chan, et al.. (2023). Comparison of two‐stage and joint TGI‐OS modeling using data from six atezolizumab clinical studies in patients with metastatic non‐small cell lung cancer. CPT Pharmacometrics & Systems Pharmacology. 13(1). 68–78. 4 indexed citations

Bruno, René, Mathilde Marchand, Kenta Yoshida, et al.. (2023). Tumor Dynamic Model-Based Decision Support for Phase Ib/II Combination Studies: A Retrospective Assessment Based on Resampling of the Phase III Study IMpower150. Clinical Cancer Research. 29(6). 1047–1055. 13 indexed citations

Kassir, Nastya, et al.. (2023). External validation of a tumor growth inhibition-overall survival model in non-small-cell lung cancer based on atezolizumab studies using alectinib data. Cancer Chemotherapy and Pharmacology. 92(3). 205–210. 4 indexed citations

Lu, Tong, Siv Jönsson, Jakob Ribbing, et al.. (2022). Population pharmacokinetic analysis of etrolizumab in patients with moderately‐to‐severely active ulcerative colitis. CPT Pharmacometrics & Systems Pharmacology. 11(9). 1244–1255. 5 indexed citations

10.

Marchand, Mathilde, Rong Zhang, Phyllis Chan, et al.. (2021). Time-dependent population PK models of single-agent atezolizumab in patients with cancer. Cancer Chemotherapy and Pharmacology. 88(2). 211–221. 24 indexed citations

11.

Chan, Phyllis, Mathilde Marchand, Kenta Yoshida, et al.. (2021). Prediction of overall survival in patients across solid tumors following atezolizumab treatments: A tumor growth inhibition–overall survival modeling framework. CPT Pharmacometrics & Systems Pharmacology. 10(10). 1171–1182. 24 indexed citations

12.

Bruno, René, Dean Bottino, Dinesh P. de Alwis, et al.. (2019). Progress and Opportunities to Advance Clinical Cancer Therapeutics Using Tumor Dynamic Models. Clinical Cancer Research. 26(8). 1787–1795. 61 indexed citations

13.

Morrissey, Kari M., Mathilde Marchand, Hina Patel, et al.. (2019). Alternative dosing regimens for atezolizumab: an example of model-informed drug development in the postmarketing setting. Cancer Chemotherapy and Pharmacology. 84(6). 1257–1267. 62 indexed citations

14.

Tardivon, Coralie, René Bruno, Benjamin Wu, et al.. (2019). Association Between Tumor Size Kinetics and Survival in Patients With Urothelial Carcinoma Treated With Atezolizumab: Implication for Patient Follow‐Up. Clinical Pharmacology & Therapeutics. 106(4). 810–820. 36 indexed citations

15.

Claret, Laurent, Jin Y. Jin, Charles Ferté, et al.. (2018). A Model of Overall Survival Predicts Treatment Outcomes with Atezolizumab versus Chemotherapy in Non–Small Cell Lung Cancer Based on Early Tumor Kinetics. Clinical Cancer Research. 24(14). 3292–3298. 53 indexed citations

16.

Claret, Laurent, et al.. (2018). Comparison of tumor size assessments in tumor growth inhibition-overall survival models with second-line colorectal cancer data from the VELOUR study. Cancer Chemotherapy and Pharmacology. 82(1). 49–54. 12 indexed citations

17.

Claret, Laurent, Manish Gupta, Kelong Han, et al.. (2013). Prediction of overall survival or progression free survival by disease control rate at week 8 is independent of ethnicity: Western versus Chinese patients with first‐line non‐small cell lung cancer treated with chemotherapy with or without bevacizumab. The Journal of Clinical Pharmacology. 54(3). 253–257. 17 indexed citations

18.

Lü, Jianfeng, René Bruno, Steve Eppler, et al.. (2008). Clinical pharmacokinetics of bevacizumab in patients with solid tumors. Cancer Chemotherapy and Pharmacology. 62(5). 779–786. 278 indexed citations

19.

Retout, Sylvie, France Mentré, & René Bruno. (2002). Fisher information matrix for non‐linear mixed‐effects models: evaluation and application for optimal design of enoxaparin population pharmacokinetics. Statistics in Medicine. 21(18). 2623–2639. 63 indexed citations

20.

Hudis, C., Andrew D. Seidman, John Crown, et al.. (1996). Phase II and pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancer.. Journal of Clinical Oncology. 14(1). 58–65. 127 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact